07:55 AM EDT, 05/16/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday that its once-weekly insulin efsitora alfa for type 2 diabetes met the primary endpoint in two late-stage clinical trials.

In both tests, efsitora showed non-inferior reduction in blood sugar levels in patients, compared to the most commonly used daily long-acting insulins, the company said.

Data showed that efsitora was equally safe and effective among adults who were new to insulin therapy and who were currently using or not using GLP-1 drugs, the company said.

Price: 784.51, Change: -2.51, Percent Change: -0.32